The Antidote: Inside the World of New Pharma (77 page)

drug-drug interactions (DDIs),
256
–57,
266
–68,
285

Duffin, Jacalyn,
165

eBay,
55
,
58
,
289

EMD Pharmaceuticals,
123
,
210

Emmens, Matthew,
228
,
240
,
309
–10,
326

background of,
123
,
164
,
184
,
188
,
210
,
260
,
283
,
310
,
357

on Boger,
184
–85,
189
,
259
,
293
,
316
,
321

and Boger’s relations with board,
162
–63

and business model and plan,
259
–60,
316
–17

CF and,
215
,
217
,
237
–38,
299
–301,
318
,
338

comparisons between Boger and,
214
,
216
–17,
237
,
288
,
318

on comparisons between Vertex and Merck,
291
–92

earnings calls and,
247
,
339
–42,
362

epilepsy and,
215
,
260
,
314

executive team of,
211
–12

on Frazier,
260
–61

HCV and,
215
–17,
237
–38,
259
–60,
262
,
288
,
300
–301,
314
,
333
,
350
,
352
,
354

Huckman’s interview with,
216
–17

illnesses of,
262
–63,
283

Incivek and,
185
,
200
–201,
207
,
211
–12,
214
–17,
222
,
231
,
233
,
242
,
244
,
256
–60,
264
,
272
,
285
–88,
291
,
299
,
303
,
316
,
318
,
321
,
329
–30,
332
,
339
,
341
,
379

influenza and,
237
,
314

Liver Meeting and,
347
,
350

long-term outlook and,
314
–15,
321
–22

management style and skills of,
198
–99,
207
,
209
–11,
259
–61,
309
,
321
–22

Merck-Roche partnership and,
284
,
287
–88

Merck’s AdComm presentation and,
267
–68

Milestone Day and,
320
–23

Morgan conference and,
214
–16,
237
–38,
360

NDAs and,
231
,
233
,
237

and Pharmasset as takeover target,
354
–55

and pressures on Mueller,
207
,
222

retirements of,
184
,
187
,
360
,
370

Smith’s financial tutorial and,
281

Smith’s relationship with,
314
–15,
325

speeches of,
214
–15,
237
–38,
300
–301,
318
–19,
321
–22

strategy-opportunity balance and,
314
,
317

succession and,
164
,
188
–89,
195
–98,
205
,
331
,
338
–39,
357
–59,
361

sustainability and,
249
,
259

on values,
217
,
261
,
330
,
332
,
341

and Vertex as takeover target,
216
–17,
331
–32

Wysenski’s relationship with,
210
–11,
218
,
370

Zenobia
and,
187
–88

Enbrel,
78
,
92
–93,
154
,
177
,
202
,
317

Endo Pharmaceuticals,
210
–11

enzymes,
16
,
53
,
206
,
318

CF and,
126
,
249
,
346

HCV and,
34
,
37
,
39
,
62
,
93
–95

HIV and,
13
–14,
17
–18,
20
,
148

epilepsy,
215
–16,
260
,
314
,
335

Ernst and Young (E&Y),
73
,
86

erythropoietin (EPO),
192
,
200
,
208
–9,
230
,
264
,
266
–67

Esbriet,
312
–13

European Association for the Study of the Liver (EASL),
182
,
258
,
261
–63

European Feudalism,
366

expanded access programs,
305
–6

Fan Pier,
240
,
321

Fauci, Anthony,
31

Feuerstein, Adam,
264
,
311
,
358
–59,
365

FierceBiotech,
372
–73,
376

financial crises,
5
,
176
,
178
–79,
186
–87,
192
,
237
,
242
,
312

First National Conference on Human Retroviruses,
25
–26,
30
–31

fiscal cliff,
6
,
377

flaviviruses,
22

Fleischer, Russ,
184
,
209

on bilirubin side effect,
270
–72

Incivek and,
171
,
223
,
228
,
270
–72

Florey, Howard,
152

Flynn, Terrence,
247

Food and Drug Administration (FDA),
15
,
46
,
65
,
71
–72,
129
–30,
157
,
163
,
208
–10,
216
–17,
310

CF and,
143
,
146
,
251
,
303
–4,
306
,
313
,
327
,
336

combination therapies and,
146
–47

EPO and,
208
–9,
264
,
266

funding of,
202

HCV and,
22
,
61
,
130
,
135
,
137
–38,
150
–51,
159
,
165
–66,
183
,
230
,
264
–76,
283
,
285
,
373

HIV and,
19
,
50
,
77
,
94
,
98
,
147

Incivek and,
168
–69,
171
,
176
,
185
,
200
,
208
–9,
216
,
222
–23,
226
–29,
233
,
238
,
240
,
243
–44,
264
–65,
268
–76,
285
,
347
,
369
,
378

JAK inhibitors and,
317
–18

Kalydeco and,
303
–4,
359
,
361
,
367
,
369
,
371
,
377
,
380
–81

Vertex’s relationship with,
137
–38,
140
,
171
,
183
–84,
200

Victrelis and,
264
–67,
273
,
275
–76,
283

Forbes
,
98
,
251

forced expiratory volume in one second (FEV1),
182
,
248
,
252
–54,
296
,
304
–5,
307
,
363
,
367
,
371
,
381

Fortune
,
178
,
278

fosamprenavir,
see
Lexiva

Fox, Ted,
34
–35,
37

France,
31
,
47
,
65
,
213

Frazier, Ken,
244
–47

Emmens on,
260
–61

Merck’s finances and,
245
–47,
283
,
311

Friedman, David,
318
–19,
321
,
331
–32

Friedman, Lawrence,
266
,
274
–75

Galson, Steven,
166
–67

Gane, Edward,
348
–49

Garrison, Bink,
115
–17,
163
,
212

and Boger’s relations with board,
115
–16,
197

Boger’s retirement and,
197
,
205

on describing Vertex,
116
–17

focus groups of,
124
,
133

hiring of,
117
,
122
,
135
,
204

Vertex’s creativity and,
161
–62

Vertex Vision Process and,
117
,
133
–34,
158
–59,
387

VIP teams and,
157
,
159

work with Hurter of,
159
–60

gastrointestinal system:

CF and,
67
,
248
–49,
254

HCV and,
113
–14,
138

Bill & Melinda Gates Foundation,
67
–68,
142

Ge Li,
174

Genentech,
65
,
144
,
226
,
244
,
295
,
321
,
354

comparisons between Vertex and,
193
,
287

Roche’s acquisition of,
185
,
188
,
200
,
243

generic drugs,
6
,
184
,
195
,
202
,
261

genes, genetics, genotypes,
24
,
56
,
84
–86,
106
,
193
,
202
,
250

CF and,
67
–69,
79
,
120
,
142
–43,
181
–82,
251
,
295
,
298
,
300
,
371
–72

HCV and,
32
–34,
39
,
47
–48,
61
,
94
–95,
137
,
147
,
150
,
183
,
261
,
275
,
348
,
356
,
358
,
373

HIV and,
17
,
147

kinases and,
53
–55

genomics,
6
,
43
,
66
,
105
,
251
,
300
,
377

chemogenomics and,
56
–57,
59
,
65
,
85
,
88

p38 and,
53
–55

George, Shelley,
209
,
256
,
258

German academic model,
108

Germany,
3
,
47
,
49
,
91
,
112
,
123
,
152
,
340
,
366

Gilead Sciences,
228
–30,
244
,
256
,
287
–88,
313
–14

comparisons between Vertex and,
193
,
197
,
283

finances of,
283
,
333
,
355
,
357
,
363
,
365

HCV and,
151
,
220
,
226
,
347
,
357
,
363
,
372
–73,
375
,
377

HIV and,
147
–48,
183
,
193
,
219
,
224
–26,
229
,
262
,
357
,
365

Pharmasset acquired by,
357
,
363

Glaxo Wellcome, GlaxoSmithKline (GSK),
372

HCV and,
375
,
378

HIV and,
35
–36,
46
,
50
,
77
,
85
,
98
,
224
–26,
242

Sanders and,
143
–44

Vertex’s partnership with,
77
,
85
,
87
,
98
,
375
,
378

Gleevec,
57
,
131
,
177

goals,
11
,
123
,
146
–47,
205
,
209
,
246
,
336
,
380

BHAG and,
116
,
158
–60,
162

Boger and,
2
–3,
7
,
43
,
45
,
56
,
65
,
85
–86,
92
,
172
,
178

CF and,
80
,
121
,
179
,
305

of Garrison,
116
–17

HCV and,
62
–63,
161
,
168
,
202
,
218